Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
16
×
boston blog main
boston top stories
eli lilly
16
×
life sciences
national blog main
new york blog main
raleigh-durham blog main
san diego blog main
san francisco blog main
seattle blog main
16
×
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
national
national top stories
new york top stories
raleigh-durham top stories
san diego top stories
san francisco top stories
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
indiana top stories
fda
clinical trials
cancer
startups
pfizer
deals
bristol-myers squibb
cancer immunotherapy
novartis
abbvie
alzheimer's disease
amgen
What
bio
roundup
drug
companies
week
drugs
fda
new
approval
days
life
moves
news
pharmaceutical
price
science
won
alzheimer’s
annual
big
biotech
black
buy
ceo
class
crispr
debut
diabetes
diamond’s
growing
migraine
nash
notes
prices
therapies
time
typically
year
acquisitions
airport
Language
unset
Current search:
biotech
×
" seattle blog main "
×
" eli lilly "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines